Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
- Upgrade from Basic Body Lotion - triple brightening actives deliver results ordinary moisturizers cannot
Read More Corxel-Vincentages oral GLP-1 meets phase II obesity endpoints Corxel Pharmaceuticals Ltd.s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results
Nature 612 , 720724 (2022)
Other GLP-1 receptor agonists such as liraglutide 3mg (Saxenda) or tirzepatide (Mounjaro, per NICE TA1026) may be considered according to local commissioning arrangements and NICE guidance
US$ 27.01
US$ 23.12
US$ 27.43
